Will brand names of recently approved metastatic PCa drugs lead to confusion among physicians or pharmacists?
In a letter to the editor published in The New England Journal of Medicine (2013;268:194), Marc B. Garnick, MD, of Beth Israel Deaconess Medical Center in Boston, took issue with the naming of new drugs for treating patients with metastatic prostate cancer.
He wrote that the “proclivity to include the letters X and Z in the marketed trade name names will undoubtedly lead to confusion both by the physician prescribing and the pharmacy dispensing these agents.”
These drugs include Zometa, Xgeva, Zytiga, and Xtandi. Renal & Urology News would like to know if urologists agree with Dr. Garnick, so please answer the following poll question.